Key Takeaways
- Margin crushed by China dumping and product development: EBITDA margin fell sharply as the company slashed dimer acid prices to defend its 75% market share against a new wave of Chinese dumping, while simultaneously absorbing one-time costs for isostearic acid trials and REACH compliance.
- Isostearic acid is the de-risking bet: The company has successfully manufactured isostearic acid, becoming the only producer in India and one of the top five globally, with initial purchase orders received and commercial revenue expected from Q3.
- Volume held up but pricing broke: Volume processed rose 3.2% QoQ, but a sudden, unanticipated demand drop in June and the need to match dumped Chinese prices caused a ~₹10 crore revenue shortfall versus expectation.
- Management is playing a deliberate "double-edged" strategy: To make isostearic acid, the company must first produce more dimer acid, which it then must sell into a depressed market to retain share, accepting near-term pain for future margin uplift.
- What to watch next quarter: Whether the stability test results from global customers arrive on schedule, the pace of commercial isostearic acid shipments, and any sign that Chinese dumping is abating or triggering government action.
The Margin Shock: China, Compliance, and Trials
- Chinese dumping is the dominant headwind: A new phenomenon starting in the last couple of months forced the company to cut finished product prices to match dumped imports, pushing material costs from 70%-72% of sales to 80%-82%.
- Market share defense at all costs: Management is explicit that it will not cede the 75% domestic market share it built over years, even if it means being a price taker and absorbing lower margins in the short term.
- Confidence it is dumping, not structural cost advantage: Nothing is coming from Europe, the company maintained 75% share profitably for years, and yields are near theoretical maximums, ruling out a technological gap.
- One-time cost stack: Isostearic acid trials caused a ₹1.5-2 crore loss from material loss, job-work charges, and utility costs, while a one-time REACH compliance registration cost of ~₹45 lakhs was needed for European exports.
- The June surprise amplified the pain: April and May were good, but an unanticipated demand drop in June caused a ₹10 crore revenue shortfall, hitting margin by an estimated ₹2.5 crores. No customers were lost and no new competition entered.
Nahoosh Jariwala: "We have to retain the market share by hook or crook and that is exactly what we are doing because it took years for us to reach a market share of 75% from 25%. Now at this stage, I do not want to lose because China is dumping and I just want to give them way to sell more. No, that's not the thing we are going head-on."
Isostearic Acid: The Margin Reset Opportunity
- Manufacturing milestone achieved: The company has successfully produced isostearic acid on its plant, with samples approved by top companies in the US, Europe, and Japan, making it the only Indian manufacturer and one of the top five globally.
- Revenue timing and scale: Initial purchase orders are in hand, stability tests at customer sites are expected to take another 2-3 months, and commercial revenue of approximately ₹25 crores per quarter is expected to begin in Q3.
- Margin uplift promised: Margins on isostearic acid are expected to be higher than current product margins, with management citing the global scarcity value of being only the 5th or 6th producer worldwide.
- The captive feedstock link: The company has stopped selling monobasic acid externally and now uses it captively to make isostearic acid, creating a strategic linkage where producing more dimer acid is necessary to feed isostearic acid production.
- No ramp-up risk: The plant is fully ready with zero ramp-up needed, the process is stabilized, and the entire team is in place.
Rajen Jhaveri: "So, it is a double-edged sword. We want to retain our market share also, we want to make more dimer acid also so that we can get more monobasic acid and so that we can make more isostearic acid. So, it is a business decision in the interest of the company only."
Demand and Volume Dynamics
- Volume growth intact despite pricing pressure: Volume processed increased 3.2% QoQ, and July and August volumes are reported as normal, though pricing remains under pressure from Chinese competition.
- The June demand drop was a blip, not a trend: The sudden June weakness was unanticipated and not attributed to customer loss or new competition, with July performance described as having "gone up reasonably well."
- Domestic exposure dominates the pain: The de-stocking impact in Q1 was entirely on domestic sales, with exports accounting for only 4% of revenue, limiting the diversification benefit.
- Volume growth as a margin lever: Management expects volume rises in the 7%-8% range, with other costs remaining largely the same, which should help improve profitability even before isostearic acid kicks in.
- Raw material volatility is a known, managed risk: Vegetable oil price swings have been a recurring disruption since the war began in February 2022, but the Chinese dumping is a distinct and newer phenomenon layered on top.
Strategy: Absorbing Pain for Future Gain
- The deliberate trade-off: Management is explicitly accepting one or two quarters of losses to secure a better future, framing the isostearic acid investment and market share defense as a calculated business decision.
- No knee-jerk reaction: Despite the margin shock, management insists no change in strategy is needed, with the ₹700 crore-plus revenue target and margin stability expectation maintained for the rest of the year.
- Government intervention expected but not relied upon: Management believes the government will eventually act on Chinese dumping because all specialty chemical companies are suffering, but the company is too small to lobby directly and is not waiting for protection.
- Chinese dumping seen as temporary: Management expects the dumping to last a maximum of two quarters, though it admits it cannot really understand how China will behave.
- New product pipeline in motion: Work is underway on one new product using the same plant, and a project on a new raw material is on track, though it may take a couple of months more as the company will be the first in India to do it.
Rajen Jhaveri: "But we are looking for the better future and for the better future you need to bear some loss in one or two quarters, then only you will get this better future."
Operational Efficiency and Cost Structure
- Employee costs are lean and stable: Manager-level and above headcount has remained unchanged for 2-3 years despite sales growth, with only operators and helpers added for new equipment.
- Full automation in place: 100% of all plants operate on Distributed Control Systems, providing a stable operational base as volumes scale.
- Biofuel plant ready but idle: The biofuel plant is complete but not manufacturing because vegetable oil prices exceed diesel prices, making production unviable; the plant has alternative applications including isostearic acid manufacturing.
- R&D spending is minimal but output-focused: R&D costs are just 0.0003% of sales, with management arguing that increasing percentage spending is not the path to better products in this industry, pointing to the in-house development of isostearic acid as evidence.
- Raw material transparency coming: Management committed to publishing a chart on the company website showing month-wise or quarterly raw material price trends to help investors track the key input cost driver.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Isostearic acid commercial revenue | ~₹25 crores per quarter incremental revenue | Starting Q3 FY24 |
| Isostearic acid stability tests | Customer-side stability testing completed | 2-3 months from now |
| Chinese dumping cessation | Dumping expected to stop | Maximum two quarters |
| Full-year revenue target | ₹700 crore-plus revenues with margin stability | Rest of FY24 |
| Q2 margin improvement | Margins should be better than Q1 | Q2 FY24 |
| Volume growth | Volume rise in 7%-8% range | Ongoing |
| New raw material project | Project on track, company will be first in India | May take "couple of months more" |
Key Metrics
| Metric | Q1 FY24 |
|---|---|
| Revenue from operations | ₹161 cr |
| EBITDA | Nearly ₹12 cr |
| EBITDA margin | 7.29% |
| Net profit after tax | Approximately ₹6 cr |
| Sales volume growth (QoQ) | 18% higher |
| Sales volume growth (YoY) | 3.2% higher |
| Quantity processed growth (YoY) | 2.8% |
| Material cost as a percentage of revenue | 80%-82%, up from 70%-72% |
| Domestic sales share | 96% of total sales |
| Export sales share | 4% of total sales |
| Linoleic acid and dimer acid share of total sales | 74%-75% |
| Paints and inks end-user share of total sales | 50% |
| Isostearic acid expected incremental revenue per quarter | ₹25 cr |
| Isostearic acid trials and related costs impact on EBITDA | ₹5 cr fall, including ₹2 cr trial loss, ₹2.5 cr June revenue impact, and ₹50 lakh legal compliance cost |
| REACH compliance one-time legal cost | Approximately ₹45 lakh |